Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, adult: Astrocytoma/Astrocytic tumors
Stage/Subtype:  pineal gland astrocytoma, adult
Country:  U.S.A.
Trial Type:  Treatment
Results 1-20 of 20 for your search:
Start Over
Light Sedation or Intubated General Anesthesia in Reducing Complications and Length of Hospital Stay in Patients With Brain Cancer Undergoing Craniotomy
Status: Active
Phase: Phase IV
Type: Supportive care, Treatment
Age: 19 and over
Trial IDs: OSU-12161, NCI-2014-01110, 2014C0007, NCT02193568
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BMX-HGG-001, NCI-2016-00288, NCT02655601
Combination Chemotherapy with or without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients with Malignant Brain Tumors
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: IRB00000922, NCI-2013-00781, CR00018679, CR00021317, CR00022743, CR00023930, eIRB #922, MR00041590, ONC-02019-L, OHSU-7328, OHSU-922, OHSU-ONC-02059-L, CASE-CCF-6385, NCT00075387
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Any age
Trial IDs: 05-122, NCI-2016-00874, MSKCC-05122, NCT00445965
Carboplatin and Bevacizumab in Treating Patients with Recurrent Ependymoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-0009, NCI-2011-01283, CERN 09-02, P152432, NCT01295944
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117019, NCI-2014-00802, NCT02034110
Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LOXO-TRK-15002, NCI-2015-01947, NCT02576431
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: ATI001-102, NCI-2014-00752, NCT02026271
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AG120-C-002, NCI-2014-00868, NCT02073994
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients with Recurrent High Grade Gliomas
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13P.528, NCI-2014-01344, 2013-12, 3007, NCT02186509
Vaccine Therapy and Temozolomide in Treating Patients with Recurrent Glioma Expressing IDH1
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00054746, NCI-2015-02213, NCT02193347
Genetically Modified T-cells in Treating Patients with Recurrent or Refractory Malignant Glioma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: 13384, NCI-2014-01488, 117388, 118810, 120959, 122340, NCT02208362
Selinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1414, NCI-2014-02410, NCT02323880
Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: KX02-01-13, NCI-2015-00135, NCT02326441
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AG881-C-002, NCI-2015-01150, NCT02481154
AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C-500-01, NCI-2016-00339, NCT02694822
iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 30
Trial IDs: GO29665, NCI-2016-00541, 2014-004685-25, NCT02639546
Conditioning Therapy Followed by Stem Cell Transplant in Treating Patients with High Risk or Relapsed Solid, Central Nervous System, or Germ Cell Tumors
Status: Active
Phase: No phase specified
Type: Treatment
Age: 70 and under
Trial IDs: 2011OC057, NCI-2013-02265, 1107M02641, MT2011-09C, NCT01505569
Pembrolizumab in Treating Patients with Recurrent Malignant Glioma with a Hypermutator Phenotype
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-227, NCI-2016-00116, NCT02658279
Topotecan Hydrochloride Using Convection-Enhanced Delivery in Treating Patients with Recurrent or Progressive High-Grade Glioma Undergoing Surgery
Status: Active
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: INFT1315, NCI-2015-01072, NCT02500459
Start Over